Tasly Darentang: Zhongxin Pharmaceutical No Longer Included in Consolidated Financial Statements

Deep News01-09

Tasly Darentang stated on an investor interactive platform on January 9th that the significant year-on-year decrease in cash paid for goods and services in the first half and third quarter of 2025 is primarily due to the company contributing its entire equity stake in its wholly-owned subsidiary, Tianjin Zhongxin Pharmaceutical Co., Ltd., as capital at the end of 2024 to increase its investment in Jinyao Taiping Pharmaceutical Co., Ltd.

Following the completion of this capital increase, Zhongxin Pharmaceutical became an associate company of Tasly Darentang and is consequently no longer included within the scope of the company's consolidated financial statements.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1163222079?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-09 22:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1163222079","market":"hk","top_or_hot":-1,"title":"Tasly Darentang: Zhongxin Pharmaceutical No Longer Included in Consolidated Financial Statements","media":"Deep News","content":"<p>Tasly Darentang stated on an investor interactive platform on January 9th that the significant year-on-year decrease in cash paid for goods and services in the first half and third quarter of 2025 is primarily due to the company contributing its entire equity stake in its wholly-owned subsidiary, Tianjin Zhongxin Pharmaceutical Co., Ltd., as capital at the end of 2024 to increase its investment in Jinyao Taiping Pharmaceutical Co., Ltd.</p>\n<p>Following the completion of this capital increase, Zhongxin Pharmaceutical became an associate company of Tasly Darentang and is consequently no longer included within the scope of the company's consolidated financial statements.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tasly Darentang: Zhongxin Pharmaceutical No Longer Included in Consolidated Financial Statements</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTasly Darentang: Zhongxin Pharmaceutical No Longer Included in Consolidated Financial Statements\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-01-09 22:41</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Tasly Darentang stated on an investor interactive platform on January 9th that the significant year-on-year decrease in cash paid for goods and services in the first half and third quarter of 2025 is primarily due to the company contributing its entire equity stake in its wholly-owned subsidiary, Tianjin Zhongxin Pharmaceutical Co., Ltd., as capital at the end of 2024 to increase its investment in Jinyao Taiping Pharmaceutical Co., Ltd.</p>\n<p>Following the completion of this capital increase, Zhongxin Pharmaceutical became an associate company of Tasly Darentang and is consequently no longer included within the scope of the company's consolidated financial statements.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0060","symbol_name":"抗癌","start_time":0,"source_url":"","article_id":"1163222079","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1163222079","pubTimestamp":1767969718,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Tasly Darentang stated on an investor interactive platform on January 9th that the significant year-on-year decrease in cash paid for goods and services in the first half and third quarter of 2025 is...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","600329":"达仁堂","BK0060":"抗癌","BK0239":"医药制造","BK0164":"国企混改","09939":"开拓药业-B","BK0028":"国家队","BK1515":"抗疫概念","BK1161":"生物科技","BK0188":"融资融券","BK1574":"生物医药B类股"},"translate_title":"天士力达仁堂：中新药业不再纳入合并财务报表","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"600329":1,"09939":1},"content_text":"Tasly Darentang stated on an investor interactive platform on January 9th that the significant year-on-year decrease in cash paid for goods and services in the first half and third quarter of 2025 is primarily due to the company contributing its entire equity stake in its wholly-owned subsidiary, Tianjin Zhongxin Pharmaceutical Co., Ltd., as capital at the end of 2024 to increase its investment in Jinyao Taiping Pharmaceutical Co., Ltd.\nFollowing the completion of this capital increase, Zhongxin Pharmaceutical became an associate company of Tasly Darentang and is consequently no longer included within the scope of the company's consolidated financial statements.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1163222079","isCrawlerRequest":true}